TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22722530
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate (DMPA) 150 mg intramuscularly every 12 weeks for 24 weeks
Study: 22722530
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive (OC) pills (ethinyl estradiol 0.03 mg and gestodene 0.075 mg) daily for 24 weeks
Study: 10974616
Drug: Cholecystokinin tetrapeptide
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin tetrapeptide (CCK‐4) injection, high doses, specific dosage not mentioned, duration not mentioned.
Study: 1611113
Drug: Interferon (IFN)‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN)‐alpha 2b (50 MU dose), intravesical therapy for 10 months, starting 21 days after TUR, once a week for 8 weeks, then once every 15 days for 4 months, and finally once a month for 4 months.
Study: 1611113
Drug: Epirubicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (80 mg) intravesically 0, 24 and 48 h after TUR, followed by IFN‐alpha 2b as in Group 1.
Study: 31959339
Drug: Cisplatin (C)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1-4 (CF)
Study: 31959339
Drug: Cisplatin (C)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1-4 plus panitumumab (P) 9 mg/kg, i.v., day 1 (CFP)
Study: 30967434
Drug: Dapagliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (5 mg and 10 mg combined)
Study: 19884426
Drug: Periarticular injections
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injections with corticosteroid (methylprednisolone acetate)
Study: 19884426
Drug: Periarticular injections
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injections without corticosteroid (no-steroid group)
Study: 17537264
Drug: Acetaminophen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4 g/day for 3 consecutive days)
Study: 11329985
Drug: Monthly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group visits with a primary care physician, nurse, and pharmacist
Study: 7988347
Drug: Dilazep dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep dihydrochloride (300 mg)
Study: 3052894
Drug: Cefotetan (CTT)
Normalized name: Cefotetan
DrugBank: Cefotetan (DB01330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotetan (CTT) 2g single preoperative dose
Study: 3052894
Drug: Cefoxitin (CFX)
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefoxitin (CFX) 2g three perioperative doses plus 0.5g metronidazole
Study: 28566227
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitor plus lamivudine (once-daily lamivudine 300 mg)
Study: 28566227
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitor monotherapy (once-daily darunavir 800 mg or coformulation of lopinavir/ritonavir)
Study: 24364193
Drug: Complex oral
Normalized name: vitamin B complex Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex oral splint procedure assisted by transcutaneous electrical nerve stimulation (TENS)
Study: 24364193
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral splint
Study: 20890666
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) therapy for 12 months
Study: 20890666
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PAP therapy)
Study: 11349245
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions plus routine inpatient treatment
Study: 11349245
Drug: Routine inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine inpatient treatment only
Study: 9152658
Drug: Intravenous procainamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procainamide (10 mg.kg‐1)
Study: 7700072
Drug: cilazapril, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril, 2.5 mg/day (n = 12)
Study: 30608395
Drug: Functional musculoskeletal
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional musculoskeletal therapy pathway
Study: 27698176
Drug: Accelerated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated care (deflation after 1 hour, 2 ml/10‐minute interval)
Study: 23782489
Drug: V7 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: V7 (10 μg of heat-killed Mycobacterium vaccae)
Study: 22379791
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Back-shu points (Xinshu (BL 15), Pishu (BL 20), Gaohuang (BL 43)), once daily for 4 weeks
Study: 20183647
Drug: ADHD on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD on stimulant medication
Study: 11956266
Drug: Allogeneic melanoma
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic melanoma vaccine for 2 years
Study: 495630
Drug: Carbenicillin plus
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin plus cefamandole by continuous infusion (C+CC)
Study: 495630
Drug: Carbenicillin plus
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin plus cefamandole by intermittent infusion (C+IC)
Study: 495630
Drug: Carbenicillin plus
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin plus tobramycin by continuous infusion (C+T)
Study: 495630
Drug: Cure rates
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cure rates regardless of antibiotic regimen
Study: 28574453
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation at 800 mg/day
Study: 19164186
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (10 mg once a day for children 10 to 24 months of age and 20 mg once a day for older children)
Study: 16490909
Drug: Zoledronic acid,
Normalized name: Zoledronic Acid, Anhydrous
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid, 4 mg (n = 32)
Study: 9255195
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of gentamicin (5.0 mg/kg)
Study: 9255195
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing of gentamicin (2.5 mg/kg)
Study: 2950659
Drug: Polychemotherapy as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polychemotherapy as a component of combined and complex therapy
Study: 24716680
Drug: Spironolactone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (15 to 45 mg daily)
Study: 23963688
Drug: 75 mg/d
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/d of ASA (aspirin)
Study: 23963688
Drug: 150 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/d of ASA (aspirin)
Study: 18503621
Drug: Fentanyl-morphine combination
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl-morphine combination (fentanyl 13.33 mug/mL and morphine 1 mg/mL)
Study: 18503621
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (2 mg/mL)
Study: 17070173
Drug: Higher cell
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cell dose (10^8 cells)
Study: 17070173
Drug: Lower cell
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower cell dose (10^7 cells)
Study: 11193721
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition with glucose/amino acids/fat
Study: 11193721
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition with glucose/amino acids
Study: 8470423
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine, 40 micrograms given at months 0, 1, 2 and 6
Study: 8470423
Drug: Booster injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster injection of 40 micrograms of hepatitis B vaccine in patients vaccinated before transplantation
Study: 2878490
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections (MI)
Study: 26942318
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of propranolol (beta-adrenergic receptor antagonist) administered at encoding
Study: 26942318
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered before memory retrieval
Study: 16797593
Drug: Pramipexole as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole as add-on therapy to levodopa
Study: 12653895
Drug: One intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One intra-arterial dose of cisplatin/lipiodol
Study: 12653895
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of cisplatin/lipiodol (once every 3 months)
Study: 10502211
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily (group A)
Study: 10502211
Drug: Coumadin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumadin plus aspirin (group CA)
Study: 1936506
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 100 mg o.d. for 1 day (87 patients)
Study: 1936506
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 100 mg b.i.d. for 1 day (83 patients)
Study: 1936506
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 100 mg o.d. for 2 days (86 patients)
Study: 7297067
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg vaginal suppository of 9-deoxo-16,16-dimethyl-9-methylene PGE2
Study: 7297067
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg vaginal suppository of 9-deoxo-16,16-dimethyl-9-methylene PGE2
Study: 7297067
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 15-methyl PGF2 alpha Tham added at 24 hours
Study: 7297067
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 15-methyl PGF2 alpha Tham added at 36 hours
Study: 7297067
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of PGE2
Study: 7297067
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 15-methyl PGF2 alpha methyl ester
Study: 23263697
Drug: Post-chemotherapy interval
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-chemotherapy interval (PCI)
Study: 21886189
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid therapy (Prednisolone, 100 mg per day for 5 days)
Study: 21886189
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral steroid (control group)
Study: 3663426
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg or 120 mg)
Study: 15040646
Drug: Macrolide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide therapy
Study: 8659773
Drug: High thoracic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High thoracic epidural anesthesia (25 mL lidocaine)
Study: 8659773
Drug: High thoracic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High thoracic epidural anesthesia (25 mL lidocaine) combined with general anesthesia
Study: 8659773
Drug: Low thoracic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low thoracic epidural anesthesia (12 mL lidocaine)
Study: 31571128
Drug: Betahistine Dihydrochloride
Normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine Dihydrochloride 16 mg
Study: 30096345
Drug: Small package
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small package size (350 g)
Study: 30096345
Drug: Large package
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large package size (1000 g)
Study: 21751769
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery treatment group
Study: 18515515
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter plus low-dose oxytocin
Study: 9660522
Drug: Barnidipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine (20 mg)
Study: 4608708
Drug: Inactivated monovalent
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated monovalent A/Hong Kong vaccine
Study: 4608708
Drug: Inactivated monovalent
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated monovalent A/England vaccine
Study: 4608708
Drug: Influenza B
Normalized name: influenza B virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza B vaccine
Study: 26649424
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (DexIV)
Study: 16628507
Drug: Computer-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based rehabilitation program (daily training for three weeks)
Study: 12587100
Drug: Most promising
Approvals — FDA: no, EMA: no, PMDA: no
Description: Most promising experimental treatments selected at first interim analysis
Study: 9441099
Drug: STH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: STH treatment (streptomycin, thiacetazone, isoniazid)
Study: 3555382
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous gammaglobulins
Study: 2406323
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (standardized Alternaria extract)
Study: 11473961
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of GnRH agonist during the luteal phase (cL group)
Study: 11473961
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol (L group)
Study: 3281057
Drug: RS‐86 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS‐86 (10 mg/d) plus glycopyrrolate (6 mg/d)
Study: 29142966
Drug: Elemental Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental Mg 30 mmol/d
Study: 29142966
Drug: Elemental Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental Mg 15 mmol/d
Study: 18242858
Drug: Exposure in
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure in vivo treatment (EXP)
Study: 26651828
Drug: Graded activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded activity treatment (GA)
Study: 20946333
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab 1.25 mg/0.05 ml
Study: 18692170
Drug: methylphenidate/behavioural treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate/behavioural treatment (BT)
Study: 9842405
Drug: Quinapril (angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (angiotensin-converting enzyme inhibitor)
Study: 8923865
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I (IGF-I) 60 micrograms/kg
Study: 30676012
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata lecithin-based delivery form (Casperome®) - one tablet/day
Study: 30676012
Drug: Standard management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard management (SM) group: diet and, if needed, hyoscine butylbromide (Buscopan®) or papaverine hydrochloride + 10 mg of Atropa belladonna extract
Study: 24494593
Drug: Computer-assisted self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted self-management plus problem-solving therapy
Study: 20735289
Drug: Immunomodulatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory therapy (IMT)
Study: 19052246
Drug: Arm ergometer
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm ergometer therapy (n = 10)
Study: 19052246
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy (n = 10)
Study: 19052246
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT) group (control) (n = 10)
Study: 15705982
Drug: Statin drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin drug therapy initiation protocol at hospital discharge
Study: 15705982
Drug: Statin drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin drug therapy initiation protocol
Study: 12907105
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg) administered intravenously 1 hour after surgery
Study: 12907105
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously 1 hour after surgery
Study: 10603730
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg iodine/week
Study: 10603730
Drug: Combined iodine/T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined iodine/T4 treatment
Study: 10603730
Drug: Single-T4 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-T4 therapy
Study: 7002482
Drug: Tolmetin sodium
Normalized name: Tolmetin Sodium
DrugBank: Tolmetin (DB00500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolmetin sodium (1600 mg daily)
Study: 7002482
Drug: Aloxiprin (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloxiprin (initially 6 g daily, reduced to 4 g daily after 3 months)
Study: 7002482
Drug: Phenylbutazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (400 mg daily)
Study: 18613809
Drug: Disulfiram (≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (≤ 250 mg/day)
Study: 1384304
Drug: Almokalant 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almokalant 4.5 mg intravenously over 10 minutes
Study: 30232642
Drug: Pre-ovulatory follicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in women with severe OHSS (n = 25)
Study: 30232642
Drug: Pre-ovulatory follicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in high-risk controls (n = 25)
Study: 30232642
Drug: Pre-ovulatory follicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in low-risk controls (n = 25)
Study: 24607076
Drug: Toxic solution
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxic solution (ionic hydroxylamine hydrochloride at 9mg/ml)
Study: 19653815
Drug: Denosumab (30/120/180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (30/120/180 mg every 4 weeks or 60/180 mg every 12 weeks)
Study: 1538156
Drug: NG-mononmethyl-L-arginine (NMA)
Normalized name: L-Ng-monomethyl Arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-mononmethyl-L-arginine (NMA)
Study: 3901170
Drug: Diltiazem (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (240 mg)
Study: 30791824
Drug: Atosiban (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (37.5 mg total dose)
Study: 26822461
Drug: Supervised group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised group exercise therapy
Study: 14710804
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise therapy
Study: 22472585
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges (Lactobacillus reuteri DSM 17938 and ATCC PTA 5289), 2/day for 6 weeks
Study: 15650887
Drug: EMG activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG activity (agonist and antagonist)